Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $90.0 million.

  • UroGen Pharma's Cash & Equivalents fell 2792.04% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.0 million, marking a year-over-year decrease of 2792.04%. This contributed to the annual value of $172.0 million for FY2024, which is 8103.51% up from last year.
  • Latest data reveals that UroGen Pharma reported Cash & Equivalents of $90.0 million as of Q3 2025, which was down 2792.04% from $92.9 million recorded in Q2 2025.
  • UroGen Pharma's Cash & Equivalents' 5-year high stood at $220.0 million during Q2 2024, with a 5-year trough of $20.1 million in Q2 2023.
  • Its 5-year average for Cash & Equivalents is $86.6 million, with a median of $90.0 million in 2025.
  • As far as peak fluctuations go, UroGen Pharma's Cash & Equivalents crashed by 6532.52% in 2023, and later skyrocketed by 99292.0% in 2024.
  • Over the past 5 years, UroGen Pharma's Cash & Equivalents (Quarter) stood at $44.4 million in 2021, then increased by 24.91% to $55.4 million in 2022, then surged by 71.46% to $95.0 million in 2023, then skyrocketed by 81.04% to $172.0 million in 2024, then crashed by 47.65% to $90.0 million in 2025.
  • Its Cash & Equivalents was $90.0 million in Q3 2025, compared to $92.9 million in Q2 2025 and $104.0 million in Q1 2025.